Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithira Vasu

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Blood Cancer Discovery|July 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJeffrey Crawford, Pamela Sue Becker, James O Armitage, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020Pamela Sue Becker, Elizabeth A Griffiths, Laura M Alwan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022Elizabeth A Griffiths, Vivek Roy, Laura Alwan, et al.
Blood Advances|April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphomaNathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Blood Neoplasia|April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemiaUma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Blood Cancer Discovery|July 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2017
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJeffrey Crawford, Pamela Sue Becker, James O Armitage, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020Pamela Sue Becker, Elizabeth A Griffiths, Laura M Alwan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022Elizabeth A Griffiths, Vivek Roy, Laura Alwan, et al.
Blood Advances|April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphomaNathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Blood Neoplasia|April 20, 2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemiaUma Borate, Cristina E Tognon, Yazan F Madanat, et al.
Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Pageof 11